查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1179679

感官障礙治療市場：按疾病類型、療法、分銷渠道分類：2021-2031 年全球機會分析和行業預測

Paresthesia Treatment Market By Disease Type, By Treatment, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日期: | 出版商: Allied Market Research | 英文 328 Pages | 商品交期: 2-3個工作天內

價格

全球感覺障礙治療市場預計到 2031 年將達到 79 億美元，2022 年至 2031 年的複合年增長率為 3.8%，2021 年價值 53.7628 億美元。

感覺異常是一種麻木或燒灼感，最常發生在手、臂、腿和腳等四肢。 它最常見於四肢，如手、手臂和腿，也可發生在身體的其他部位。 當您長時間坐在腳或腿上時，會出現同樣的“緊繃感”。 當手臂或腿部的神經受到一定壓力時，就會發生這種情況。 當壓力消失時，不適感就消失了。 有些人有慢性感覺缺陷，這是更嚴重的神經損傷或病症的跡象。 感覺障礙的原因包括中風、多發性硬化症、脊髓和腦腫瘤、高水平的維生素 D 和其他維生素、糖尿病、纖維肌痛、高血壓、感染、神經損傷以及神經壓迫或擠壓。 感覺異常的症狀包括刺痛或“針刺”感、疼痛或灼痛、受影響區域的麻木或感覺喪失、感覺受影響區域“睡著了”、刺痛或瘙癢以及皮膚灼痛或燒灼感.包括寒冷。

由於癌症等疾病的患病率上升、人口迅速老齡化以及食物中缺乏足夠的營養，預計在預測期內，全球感覺障礙治療市場將出現顯著增長。 此外，人口中不斷增加的感官障礙、不良生活方式和不斷上升的醫療保健成本也對市場增長做出了重大貢獻。 然而，藥物在治療方面的低效以及當局對藥物審批的嚴格監管規定對市場的增長產生了負面影響。 相反，為更好的治療而進行的研發投資激增為市場增長提供了有利可圖的機會。

內容

第一章介紹

第 2 章執行摘要

第 3 章市場概述

  • 市場定義和範圍
  • 主要發現
    • 主要投資領域
  • 波特的五力分析
  • 主要公司的定位
  • 市場動態
    • 司機
    • 約束因素
    • 機會
  • COVID-19 影響分析

第 4 章感覺障礙治療市場：按疾病類型分類

  • 概覽
    • 市場規模和預測
  • 急性感覺減退
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：國家分析
    • 急性感覺障礙治療市場：按年齡組分類
  • 慢性感覺障礙
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
    • 慢性感覺異常治療市場：按年齡組分類

第 5 章感覺障礙治療市場：按治療分類

  • 概覽
    • 市場規模和預測
  • 免疫抑製劑
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 抗驚厥藥
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 外用霜
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 抗病毒劑
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 其他
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類

第 6 章。感覺障礙治療市場：按分銷渠道

  • 概覽
    • 市場規模和預測
  • 醫院藥房
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 零售藥房
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 在線藥店
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類

第 7 章。感覺障礙治療市場：按地區

  • 概覽
    • 市場規模和預測
  • 北美
    • 主要趨勢和機會
    • 北美市場規模和預測：按疾病類型
    • 北美市場規模和預測：按處理方法
    • 北美市場規模和預測：按分銷渠道
    • 北美市場規模和預測：按國家/地區分類
      • 美國
      • 加拿大
      • 墨西哥
  • 歐洲
    • 主要趨勢和機會
    • 歐洲市場規模和預測：按疾病類型
    • 歐洲市場規模和預測：按處理方法
    • 歐洲市場規模和預測：按分銷渠道
    • 歐洲市場規模和預測：按國家/地區分類
      • 法國
      • 德國
      • 英國
      • 意大利
      • 西班牙
      • 其他歐洲
  • 亞太地區
    • 主要趨勢和機會
    • 亞太地區市場規模和按疾病類型預測
    • 亞太地區市場規模和按處理方法預測
    • 亞太市場規模和預測：按分銷渠道
    • 亞太地區的市場規模和預測：按國家/地區分類
      • 日本
      • 中國
      • 印度
      • 澳大利亞
      • 韓國
      • 台灣
      • 其他亞太地區
  • 拉美
    • 主要趨勢和機會
    • LAMEA 市場規模和預測：按疾病類型
    • LAMEA 市場規模和預測：按處理方法
    • LAMEA 市場規模和預測：按分銷渠道
    • LAMEA 市場規模和預測：按國家/地區分類
      • 巴西
      • 土耳其
      • 委內瑞拉
      • 沙特阿拉伯
      • 南非
      • 其他拉美地區

第八章公司情況

  • 簡介
  • 關鍵成功策略
  • 10 家主要公司的產品映射
  • 比賽儀表板
  • 競爭熱圖
  • 主要發展

第九章公司簡介

  • Abbott Laboratories
  • AbbVie Inc.
  • Baxter International Inc.
  • Bio-Medical Research Ltd.
  • Boston Scientific Corporation
  • Cipla Ltd.
  • Cyberonics, Inc.
  • EnteroMedics Inc.
  • GlaxoSmithKline plc.
  • Glenmark
  • Medtronic
  • Merck
  • Nevro Corp.
  • Omron Healthcare, Inc.
  • Pfizer
  • Stimwave LLC
  • Stryker Corp.
Product Code: A17080

The global paresthesia treatment market was valued at $5,376.28 million in 2021, and is projected to reach $7,900.0 million by 2031, registering a CAGR of 3.8% from 2022 to 2031.

Paresthesia is numbness and a burning feeling that occurs most often in the extremities, such as the hands, arms, legs, or feet. It can occur elsewhere in the body as well. It is the same "pins and needles" feeling that happens when someone sits on their leg or foot for too long. It is caused when the nerves of arms and legs are under any kind of pressure. The discomfort goes away, once that pressure is relieved. Some people may have chronic paresthesia, which could be a sign of a more serious nerve injury or condition. Some of the causes of paresthesia include stroke, multiple sclerosis, tumor in the spinal cord or brain, high levels of vitamin D or other vitamins, diabetes, fibromyalgia, high blood pressure, infection, nerve injury, and compressed or pinched nerve. The symptoms of paresthesia include tingling or a "pins and needles" sensation, aching or burning pain, numbness or poor feeling in the affected area, a feeling that the affected area has "fallen asleep", prickling or itching feeling, and hot or cold skin.

The global paresthesia treatment market is anticipated to show significant market growth during the forecast period, owing to rise in the prevalence of disease such as cancer, surge in geriatric population, and lack of proper nutrients in the food. Furthermore, increase in prevalence of paresthesia among the population, poor lifestyle, and surge in healthcare expenditure considerably contribute toward the market growth. However, low effectiveness of medicines associated with the treatment and stringent regulatory rules of the authority for the approvals of the medicines negatively impact the market growth. Conversely, the surge in investments in the research and developments (R&Ds) for better treatment offers lucrative opportunities for the growth of the market.

The paresthesia treatment market is segmented on the basis of disease type, treatment, distribution channel, and region. By disease type, the market is bifurcated into acute paresthesia and chronic paresthesia. Furthermore, the acute paresthesia is sub-classified as pediatric and adult. The chronic paresthesia segment is sub-classified as pediatric and adult. By treatment, the market is fragmented into immunosuppressant, anticonvulsants, topical creams, antivirals, and others. By distribution channel, the market is divided into hospital pharmacy, retail pharmacy, and online pharmacy. Region wise, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, Taiwan and Rest of Asia-Pacific), and LAMEA (Brazil, Turkey, Venezuela, South Africa, Saudi Arabia, and Rest of LAMEA).

The major companies profiled in the report include: Abbott Laboratories, AbbVie Inc., Baxter International Inc., Bio-Medical Research Ltd., Boston Scientific Corporation,  Cipla Ltd., Cyberonics, Inc., GlaxoSmithKline plc., Glenmark Pharmaceuticals, Medtronic plc, Merck KGaA, NeuroBo Pharmaceuticals, Inc., Nevro Corporation, Omron Healthcare, Inc. , Pfizer Inc., Reshape Lifesciences Inc., and Stimwave, LLC.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the paresthesia treatment market analysis from 2021 to 2031 to identify the prevailing paresthesia treatment market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the paresthesia treatment market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global paresthesia treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Disease Type

  • Acute Paresthesia
    • Age Group
    • Adult
    • Geriatric
  • Chronic Paresthesia
    • Age Group
    • Adult
    • Geriatric

By Treatment

  • Immunosuppressant
  • Anticonvulsants
  • Topical Creams
  • Antivirals
  • Others

By Distribution Channel

  • Online Pharmacy
  • Hospital Pharmacy
  • Retail Pharmacy

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Spain
    • Rest of Europe
    • France
    • Germany
    • UK
    • Italy
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Taiwan
    • Rest Of Asia Pacific
  • LAMEA
    • Brazil
    • Turkey
    • Venezuela
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
  • Key Market Players
    • Abbott Laboratories
    • AbbVie Inc.
    • Baxter International Inc.
    • Bio-Medical Research Ltd.
    • Boston Scientific Corporation
    • Cipla Ltd.
    • Cyberonics, Inc.
    • EnteroMedics Inc.
    • GlaxoSmithKline plc.
    • Glenmark
    • Medtronic
    • Merck
    • Nevro Corp.
    • Omron Healthcare, Inc.
    • Pfizer
    • Stimwave LLC
    • Stryker Corp.

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: PARESTHESIA TREATMENT MARKET, BY DISEASE TYPE

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Acute Paresthesia
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market analysis by country
    • 4.2.4 Acute Paresthesia Paresthesia Treatment Market by Age Group
  • 4.3 Chronic Paresthesia
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market analysis by country
    • 4.3.4 Chronic Paresthesia Paresthesia Treatment Market by Age Group

CHAPTER 5: PARESTHESIA TREATMENT MARKET, BY TREATMENT

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Immunosuppressant
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market analysis by country
  • 5.3 Anticonvulsants
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market analysis by country
  • 5.4 Topical Creams
    • 5.4.1 Key market trends, growth factors and opportunities
    • 5.4.2 Market size and forecast, by region
    • 5.4.3 Market analysis by country
  • 5.5 Antivirals
    • 5.5.1 Key market trends, growth factors and opportunities
    • 5.5.2 Market size and forecast, by region
    • 5.5.3 Market analysis by country
  • 5.6 Others
    • 5.6.1 Key market trends, growth factors and opportunities
    • 5.6.2 Market size and forecast, by region
    • 5.6.3 Market analysis by country

CHAPTER 6: PARESTHESIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Hospital Pharmacy
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market analysis by country
  • 6.3 Retail Pharmacy
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market analysis by country
  • 6.4 Online Pharmacy
    • 6.4.1 Key market trends, growth factors and opportunities
    • 6.4.2 Market size and forecast, by region
    • 6.4.3 Market analysis by country

CHAPTER 7: PARESTHESIA TREATMENT MARKET, BY REGION

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 North America
    • 7.2.1 Key trends and opportunities
    • 7.2.2 North America Market size and forecast, by Disease Type
    • 7.2.3 North America Market size and forecast, by Treatment
    • 7.2.4 North America Market size and forecast, by Distribution Channel
    • 7.2.5 North America Market size and forecast, by country
      • 7.2.5.1 U.S.
      • 7.2.5.1.1 Market size and forecast, by Disease Type
      • 7.2.5.1.2 Market size and forecast, by Treatment
      • 7.2.5.1.3 Market size and forecast, by Distribution Channel
      • 7.2.5.2 Canada
      • 7.2.5.2.1 Market size and forecast, by Disease Type
      • 7.2.5.2.2 Market size and forecast, by Treatment
      • 7.2.5.2.3 Market size and forecast, by Distribution Channel
      • 7.2.5.3 Mexico
      • 7.2.5.3.1 Market size and forecast, by Disease Type
      • 7.2.5.3.2 Market size and forecast, by Treatment
      • 7.2.5.3.3 Market size and forecast, by Distribution Channel
  • 7.3 Europe
    • 7.3.1 Key trends and opportunities
    • 7.3.2 Europe Market size and forecast, by Disease Type
    • 7.3.3 Europe Market size and forecast, by Treatment
    • 7.3.4 Europe Market size and forecast, by Distribution Channel
    • 7.3.5 Europe Market size and forecast, by country
      • 7.3.5.1 France
      • 7.3.5.1.1 Market size and forecast, by Disease Type
      • 7.3.5.1.2 Market size and forecast, by Treatment
      • 7.3.5.1.3 Market size and forecast, by Distribution Channel
      • 7.3.5.2 Germany
      • 7.3.5.2.1 Market size and forecast, by Disease Type
      • 7.3.5.2.2 Market size and forecast, by Treatment
      • 7.3.5.2.3 Market size and forecast, by Distribution Channel
      • 7.3.5.3 UK
      • 7.3.5.3.1 Market size and forecast, by Disease Type
      • 7.3.5.3.2 Market size and forecast, by Treatment
      • 7.3.5.3.3 Market size and forecast, by Distribution Channel
      • 7.3.5.4 Italy
      • 7.3.5.4.1 Market size and forecast, by Disease Type
      • 7.3.5.4.2 Market size and forecast, by Treatment
      • 7.3.5.4.3 Market size and forecast, by Distribution Channel
      • 7.3.5.5 Spain
      • 7.3.5.5.1 Market size and forecast, by Disease Type
      • 7.3.5.5.2 Market size and forecast, by Treatment
      • 7.3.5.5.3 Market size and forecast, by Distribution Channel
      • 7.3.5.6 Rest of Europe
      • 7.3.5.6.1 Market size and forecast, by Disease Type
      • 7.3.5.6.2 Market size and forecast, by Treatment
      • 7.3.5.6.3 Market size and forecast, by Distribution Channel
  • 7.4 Asia-Pacific
    • 7.4.1 Key trends and opportunities
    • 7.4.2 Asia-Pacific Market size and forecast, by Disease Type
    • 7.4.3 Asia-Pacific Market size and forecast, by Treatment
    • 7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
    • 7.4.5 Asia-Pacific Market size and forecast, by country
      • 7.4.5.1 Japan
      • 7.4.5.1.1 Market size and forecast, by Disease Type
      • 7.4.5.1.2 Market size and forecast, by Treatment
      • 7.4.5.1.3 Market size and forecast, by Distribution Channel
      • 7.4.5.2 China
      • 7.4.5.2.1 Market size and forecast, by Disease Type
      • 7.4.5.2.2 Market size and forecast, by Treatment
      • 7.4.5.2.3 Market size and forecast, by Distribution Channel
      • 7.4.5.3 India
      • 7.4.5.3.1 Market size and forecast, by Disease Type
      • 7.4.5.3.2 Market size and forecast, by Treatment
      • 7.4.5.3.3 Market size and forecast, by Distribution Channel
      • 7.4.5.4 Australia
      • 7.4.5.4.1 Market size and forecast, by Disease Type
      • 7.4.5.4.2 Market size and forecast, by Treatment
      • 7.4.5.4.3 Market size and forecast, by Distribution Channel
      • 7.4.5.5 South Korea
      • 7.4.5.5.1 Market size and forecast, by Disease Type
      • 7.4.5.5.2 Market size and forecast, by Treatment
      • 7.4.5.5.3 Market size and forecast, by Distribution Channel
      • 7.4.5.6 Taiwan
      • 7.4.5.6.1 Market size and forecast, by Disease Type
      • 7.4.5.6.2 Market size and forecast, by Treatment
      • 7.4.5.6.3 Market size and forecast, by Distribution Channel
      • 7.4.5.7 Rest Of Asia Pacific
      • 7.4.5.7.1 Market size and forecast, by Disease Type
      • 7.4.5.7.2 Market size and forecast, by Treatment
      • 7.4.5.7.3 Market size and forecast, by Distribution Channel
  • 7.5 LAMEA
    • 7.5.1 Key trends and opportunities
    • 7.5.2 LAMEA Market size and forecast, by Disease Type
    • 7.5.3 LAMEA Market size and forecast, by Treatment
    • 7.5.4 LAMEA Market size and forecast, by Distribution Channel
    • 7.5.5 LAMEA Market size and forecast, by country
      • 7.5.5.1 Brazil
      • 7.5.5.1.1 Market size and forecast, by Disease Type
      • 7.5.5.1.2 Market size and forecast, by Treatment
      • 7.5.5.1.3 Market size and forecast, by Distribution Channel
      • 7.5.5.2 Turkey
      • 7.5.5.2.1 Market size and forecast, by Disease Type
      • 7.5.5.2.2 Market size and forecast, by Treatment
      • 7.5.5.2.3 Market size and forecast, by Distribution Channel
      • 7.5.5.3 Venezuela
      • 7.5.5.3.1 Market size and forecast, by Disease Type
      • 7.5.5.3.2 Market size and forecast, by Treatment
      • 7.5.5.3.3 Market size and forecast, by Distribution Channel
      • 7.5.5.4 Saudi Arabia
      • 7.5.5.4.1 Market size and forecast, by Disease Type
      • 7.5.5.4.2 Market size and forecast, by Treatment
      • 7.5.5.4.3 Market size and forecast, by Distribution Channel
      • 7.5.5.5 South Africa
      • 7.5.5.5.1 Market size and forecast, by Disease Type
      • 7.5.5.5.2 Market size and forecast, by Treatment
      • 7.5.5.5.3 Market size and forecast, by Distribution Channel
      • 7.5.5.6 Rest of LAMEA
      • 7.5.5.6.1 Market size and forecast, by Disease Type
      • 7.5.5.6.2 Market size and forecast, by Treatment
      • 7.5.5.6.3 Market size and forecast, by Distribution Channel

CHAPTER 8: COMPANY LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

  • 9.1 Abbott Laboratories
    • 9.1.1 Company overview
    • 9.1.2 Company snapshot
    • 9.1.3 Operating business segments
    • 9.1.4 Product portfolio
    • 9.1.5 Business performance
    • 9.1.6 Key strategic moves and developments
  • 9.2 AbbVie Inc.
    • 9.2.1 Company overview
    • 9.2.2 Company snapshot
    • 9.2.3 Operating business segments
    • 9.2.4 Product portfolio
    • 9.2.5 Business performance
    • 9.2.6 Key strategic moves and developments
  • 9.3 Baxter International Inc.
    • 9.3.1 Company overview
    • 9.3.2 Company snapshot
    • 9.3.3 Operating business segments
    • 9.3.4 Product portfolio
    • 9.3.5 Business performance
    • 9.3.6 Key strategic moves and developments
  • 9.4 Bio-Medical Research Ltd.
    • 9.4.1 Company overview
    • 9.4.2 Company snapshot
    • 9.4.3 Operating business segments
    • 9.4.4 Product portfolio
    • 9.4.5 Business performance
    • 9.4.6 Key strategic moves and developments
  • 9.5 Boston Scientific Corporation
    • 9.5.1 Company overview
    • 9.5.2 Company snapshot
    • 9.5.3 Operating business segments
    • 9.5.4 Product portfolio
    • 9.5.5 Business performance
    • 9.5.6 Key strategic moves and developments
  • 9.6 Cipla Ltd.
    • 9.6.1 Company overview
    • 9.6.2 Company snapshot
    • 9.6.3 Operating business segments
    • 9.6.4 Product portfolio
    • 9.6.5 Business performance
    • 9.6.6 Key strategic moves and developments
  • 9.7 Cyberonics, Inc.
    • 9.7.1 Company overview
    • 9.7.2 Company snapshot
    • 9.7.3 Operating business segments
    • 9.7.4 Product portfolio
    • 9.7.5 Business performance
    • 9.7.6 Key strategic moves and developments
  • 9.8 EnteroMedics Inc.
    • 9.8.1 Company overview
    • 9.8.2 Company snapshot
    • 9.8.3 Operating business segments
    • 9.8.4 Product portfolio
    • 9.8.5 Business performance
    • 9.8.6 Key strategic moves and developments
  • 9.9 GlaxoSmithKline plc.
    • 9.9.1 Company overview
    • 9.9.2 Company snapshot
    • 9.9.3 Operating business segments
    • 9.9.4 Product portfolio
    • 9.9.5 Business performance
    • 9.9.6 Key strategic moves and developments
  • 9.10 Glenmark
    • 9.10.1 Company overview
    • 9.10.2 Company snapshot
    • 9.10.3 Operating business segments
    • 9.10.4 Product portfolio
    • 9.10.5 Business performance
    • 9.10.6 Key strategic moves and developments
  • 9.11 Medtronic
    • 9.11.1 Company overview
    • 9.11.2 Company snapshot
    • 9.11.3 Operating business segments
    • 9.11.4 Product portfolio
    • 9.11.5 Business performance
    • 9.11.6 Key strategic moves and developments
  • 9.12 Merck
    • 9.12.1 Company overview
    • 9.12.2 Company snapshot
    • 9.12.3 Operating business segments
    • 9.12.4 Product portfolio
    • 9.12.5 Business performance
    • 9.12.6 Key strategic moves and developments
  • 9.13 Nevro Corp.
    • 9.13.1 Company overview
    • 9.13.2 Company snapshot
    • 9.13.3 Operating business segments
    • 9.13.4 Product portfolio
    • 9.13.5 Business performance
    • 9.13.6 Key strategic moves and developments
  • 9.14 Omron Healthcare, Inc.
    • 9.14.1 Company overview
    • 9.14.2 Company snapshot
    • 9.14.3 Operating business segments
    • 9.14.4 Product portfolio
    • 9.14.5 Business performance
    • 9.14.6 Key strategic moves and developments
  • 9.15 Pfizer
    • 9.15.1 Company overview
    • 9.15.2 Company snapshot
    • 9.15.3 Operating business segments
    • 9.15.4 Product portfolio
    • 9.15.5 Business performance
    • 9.15.6 Key strategic moves and developments
  • 9.16 Stimwave LLC
    • 9.16.1 Company overview
    • 9.16.2 Company snapshot
    • 9.16.3 Operating business segments
    • 9.16.4 Product portfolio
    • 9.16.5 Business performance
    • 9.16.6 Key strategic moves and developments
  • 9.17 Stryker Corp.
    • 9.17.1 Company overview
    • 9.17.2 Company snapshot
    • 9.17.3 Operating business segments
    • 9.17.4 Product portfolio
    • 9.17.5 Business performance
    • 9.17.6 Key strategic moves and developments

LIST OF TABLES

  • TABLE 1. GLOBAL PARESTHESIA TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 2. PARESTHESIA TREATMENT MARKET SIZE, FOR ACUTE PARESTHESIA, BY REGION, 2021-2031 ($MILLION)
  • TABLE 3. PARESTHESIA TREATMENT MARKET FOR ACUTE PARESTHESIA, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 4. GLOBAL ACUTE PARESTHESIA PARESTHESIA TREATMENT MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
  • TABLE 5. PARESTHESIA TREATMENT MARKET SIZE, FOR CHRONIC PARESTHESIA, BY REGION, 2021-2031 ($MILLION)
  • TABLE 6. PARESTHESIA TREATMENT MARKET FOR CHRONIC PARESTHESIA, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 7. GLOBAL CHRONIC PARESTHESIA PARESTHESIA TREATMENT MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
  • TABLE 8. GLOBAL PARESTHESIA TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 9. PARESTHESIA TREATMENT MARKET SIZE, FOR IMMUNOSUPPRESSANT, BY REGION, 2021-2031 ($MILLION)
  • TABLE 10. PARESTHESIA TREATMENT MARKET FOR IMMUNOSUPPRESSANT, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 11. PARESTHESIA TREATMENT MARKET SIZE, FOR ANTICONVULSANTS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 12. PARESTHESIA TREATMENT MARKET FOR ANTICONVULSANTS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 13. PARESTHESIA TREATMENT MARKET SIZE, FOR TOPICAL CREAMS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 14. PARESTHESIA TREATMENT MARKET FOR TOPICAL CREAMS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 15. PARESTHESIA TREATMENT MARKET SIZE, FOR ANTIVIRALS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 16. PARESTHESIA TREATMENT MARKET FOR ANTIVIRALS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 17. PARESTHESIA TREATMENT MARKET SIZE, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 18. PARESTHESIA TREATMENT MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 19. GLOBAL PARESTHESIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 20. PARESTHESIA TREATMENT MARKET SIZE, FOR HOSPITAL PHARMACY, BY REGION, 2021-2031 ($MILLION)
  • TABLE 21. PARESTHESIA TREATMENT MARKET FOR HOSPITAL PHARMACY, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 22. PARESTHESIA TREATMENT MARKET SIZE, FOR RETAIL PHARMACY, BY REGION, 2021-2031 ($MILLION)
  • TABLE 23. PARESTHESIA TREATMENT MARKET FOR RETAIL PHARMACY, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 24. PARESTHESIA TREATMENT MARKET SIZE, FOR ONLINE PHARMACY, BY REGION, 2021-2031 ($MILLION)
  • TABLE 25. PARESTHESIA TREATMENT MARKET FOR ONLINE PHARMACY, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 26. PARESTHESIA TREATMENT MARKET, BY REGION, 2021-2031 ($MILLION)
  • TABLE 27. NORTH AMERICA PARESTHESIA TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 28. NORTH AMERICA PARESTHESIA TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 29. NORTH AMERICA PARESTHESIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 30. NORTH AMERICA PARESTHESIA TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 31. U.S. PARESTHESIA TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 32. U.S. PARESTHESIA TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 33. U.S. PARESTHESIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 34. CANADA PARESTHESIA TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 35. CANADA PARESTHESIA TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 36. CANADA PARESTHESIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 37. MEXICO PARESTHESIA TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 38. MEXICO PARESTHESIA TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 39. MEXICO PARESTHESIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 40. EUROPE PARESTHESIA TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 41. EUROPE PARESTHESIA TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 42. EUROPE PARESTHESIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 43. EUROPE PARESTHESIA TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 44. FRANCE PARESTHESIA TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 45. FRANCE PARESTHESIA TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 46. FRANCE PARESTHESIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 47. GERMANY PARESTHESIA TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 48. GERMANY PARESTHESIA TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 49. GERMANY PARESTHESIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 50. UK PARESTHESIA TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 51. UK PARESTHESIA TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 52. UK PARESTHESIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 53. ITALY PARESTHESIA TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 54. ITALY PARESTHESIA TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 55. ITALY PARESTHESIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 56. SPAIN PARESTHESIA TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 57. SPAIN PARESTHESIA TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 58. SPAIN PARESTHESIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 59. REST OF EUROPE PARESTHESIA TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 60. REST OF EUROPE PARESTHESIA TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 61. REST OF EUROPE PARESTHESIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 62. ASIA-PACIFIC PARESTHESIA TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 63. ASIA-PACIFIC PARESTHESIA TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 64. ASIA-PACIFIC PARESTHESIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 65. ASIA-PACIFIC PARESTHESIA TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 66. JAPAN PARESTHESIA TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 67. JAPAN PARESTHESIA TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 68. JAPAN PARESTHESIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 69. CHINA PARESTHESIA TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 70. CHINA PARESTHESIA TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 71. CHINA PARESTHESIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 72. INDIA PARESTHESIA TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 73. INDIA PARESTHESIA TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 74. INDIA PARESTHESIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 75. AUSTRALIA PARESTHESIA TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 76. AUSTRALIA PARESTHESIA TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 77. AUSTRALIA PARESTHESIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 78. SOUTH KOREA PARESTHESIA TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 79. SOUTH KOREA PARESTHESIA TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 80. SOUTH KOREA PARESTHESIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 81. TAIWAN PARESTHESIA TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 82. TAIWAN PARESTHESIA TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 83. TAIWAN PARESTHESIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 84. REST OF ASIA PACIFIC PARESTHESIA TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 85. REST OF ASIA PACIFIC PARESTHESIA TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 86. REST OF ASIA PACIFIC PARESTHESIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 87. LAMEA PARESTHESIA TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 88. LAMEA PARESTHESIA TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 89. LAMEA PARESTHESIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 90. LAMEA PARESTHESIA TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 91. BRAZIL PARESTHESIA TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 92. BRAZIL PARESTHESIA TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 93. BRAZIL PARESTHESIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 94. TURKEY PARESTHESIA TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 95. TURKEY PARESTHESIA TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 96. TURKEY PARESTHESIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 97. VENEZUELA PARESTHESIA TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 98. VENEZUELA PARESTHESIA TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 99. VENEZUELA PARESTHESIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 100. SAUDI ARABIA PARESTHESIA TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 101. SAUDI ARABIA PARESTHESIA TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 102. SAUDI ARABIA PARESTHESIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 103. SOUTH AFRICA PARESTHESIA TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 104. SOUTH AFRICA PARESTHESIA TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 105. SOUTH AFRICA PARESTHESIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 106. REST OF LAMEA PARESTHESIA TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 107. REST OF LAMEA PARESTHESIA TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 108. REST OF LAMEA PARESTHESIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 109.ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 110.ABBOTT LABORATORIES: OPERATING SEGMENTS
  • TABLE 111.ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 112.ABBOTT LABORATORIES: NET SALES,
  • TABLE 113.ABBOTT LABORATORIES: KEY STRATERGIES
  • TABLE 114.ABBVIE INC.: COMPANY SNAPSHOT
  • TABLE 115.ABBVIE INC.: OPERATING SEGMENTS
  • TABLE 116.ABBVIE INC.: PRODUCT PORTFOLIO
  • TABLE 117.ABBVIE INC.: NET SALES,
  • TABLE 118.ABBVIE INC.: KEY STRATERGIES
  • TABLE 119.BAXTER INTERNATIONAL INC.: COMPANY SNAPSHOT
  • TABLE 120.BAXTER INTERNATIONAL INC.: OPERATING SEGMENTS
  • TABLE 121.BAXTER INTERNATIONAL INC.: PRODUCT PORTFOLIO
  • TABLE 122.BAXTER INTERNATIONAL INC.: NET SALES,
  • TABLE 123.BAXTER INTERNATIONAL INC.: KEY STRATERGIES
  • TABLE 124.BIO-MEDICAL RESEARCH LTD.: COMPANY SNAPSHOT
  • TABLE 125.BIO-MEDICAL RESEARCH LTD.: OPERATING SEGMENTS
  • TABLE 126.BIO-MEDICAL RESEARCH LTD.: PRODUCT PORTFOLIO
  • TABLE 127.BIO-MEDICAL RESEARCH LTD.: NET SALES,
  • TABLE 128.BIO-MEDICAL RESEARCH LTD.: KEY STRATERGIES
  • TABLE 129.BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT
  • TABLE 130.BOSTON SCIENTIFIC CORPORATION: OPERATING SEGMENTS
  • TABLE 131.BOSTON SCIENTIFIC CORPORATION: PRODUCT PORTFOLIO
  • TABLE 132.BOSTON SCIENTIFIC CORPORATION: NET SALES,
  • TABLE 133.BOSTON SCIENTIFIC CORPORATION: KEY STRATERGIES
  • TABLE 134.CIPLA LTD.: COMPANY SNAPSHOT
  • TABLE 135.CIPLA LTD.: OPERATING SEGMENTS
  • TABLE 136.CIPLA LTD.: PRODUCT PORTFOLIO
  • TABLE 137.CIPLA LTD.: NET SALES,
  • TABLE 138.CIPLA LTD.: KEY STRATERGIES
  • TABLE 139.CYBERONICS, INC.: COMPANY SNAPSHOT
  • TABLE 140.CYBERONICS, INC.: OPERATING SEGMENTS
  • TABLE 141.CYBERONICS, INC.: PRODUCT PORTFOLIO
  • TABLE 142.CYBERONICS, INC.: NET SALES,
  • TABLE 143.CYBERONICS, INC.: KEY STRATERGIES
  • TABLE 144.ENTEROMEDICS INC.: COMPANY SNAPSHOT
  • TABLE 145.ENTEROMEDICS INC.: OPERATING SEGMENTS
  • TABLE 146.ENTEROMEDICS INC.: PRODUCT PORTFOLIO
  • TABLE 147.ENTEROMEDICS INC.: NET SALES,
  • TABLE 148.ENTEROMEDICS INC.: KEY STRATERGIES
  • TABLE 149.GLAXOSMITHKLINE PLC.: COMPANY SNAPSHOT
  • TABLE 150.GLAXOSMITHKLINE PLC.: OPERATING SEGMENTS
  • TABLE 151.GLAXOSMITHKLINE PLC.: PRODUCT PORTFOLIO
  • TABLE 152.GLAXOSMITHKLINE PLC.: NET SALES,
  • TABLE 153.GLAXOSMITHKLINE PLC.: KEY STRATERGIES
  • TABLE 154.GLENMARK: COMPANY SNAPSHOT
  • TABLE 155.GLENMARK: OPERATING SEGMENTS
  • TABLE 156.GLENMARK: PRODUCT PORTFOLIO
  • TABLE 157.GLENMARK: NET SALES,
  • TABLE 158.GLENMARK: KEY STRATERGIES
  • TABLE 159.MEDTRONIC: COMPANY SNAPSHOT
  • TABLE 160.MEDTRONIC: OPERATING SEGMENTS
  • TABLE 161.MEDTRONIC: PRODUCT PORTFOLIO
  • TABLE 162.MEDTRONIC: NET SALES,
  • TABLE 163.MEDTRONIC: KEY STRATERGIES
  • TABLE 164.MERCK: COMPANY SNAPSHOT
  • TABLE 165.MERCK: OPERATING SEGMENTS
  • TABLE 166.MERCK: PRODUCT PORTFOLIO
  • TABLE 167.MERCK: NET SALES,
  • TABLE 168.MERCK: KEY STRATERGIES
  • TABLE 169.NEVRO CORP.: COMPANY SNAPSHOT
  • TABLE 170.NEVRO CORP.: OPERATING SEGMENTS
  • TABLE 171.NEVRO CORP.: PRODUCT PORTFOLIO
  • TABLE 172.NEVRO CORP.: NET SALES,
  • TABLE 173.NEVRO CORP.: KEY STRATERGIES
  • TABLE 174.OMRON HEALTHCARE, INC.: COMPANY SNAPSHOT
  • TABLE 175.OMRON HEALTHCARE, INC.: OPERATING SEGMENTS
  • TABLE 176.OMRON HEALTHCARE, INC.: PRODUCT PORTFOLIO
  • TABLE 177.OMRON HEALTHCARE, INC.: NET SALES,
  • TABLE 178.OMRON HEALTHCARE, INC.: KEY STRATERGIES
  • TABLE 179.PFIZER: COMPANY SNAPSHOT
  • TABLE 180.PFIZER: OPERATING SEGMENTS
  • TABLE 181.PFIZER: PRODUCT PORTFOLIO
  • TABLE 182.PFIZER: NET SALES,
  • TABLE 183.PFIZER: KEY STRATERGIES
  • TABLE 184.STIMWAVE LLC: COMPANY SNAPSHOT
  • TABLE 185.STIMWAVE LLC: OPERATING SEGMENTS
  • TABLE 186.STIMWAVE LLC: PRODUCT PORTFOLIO
  • TABLE 187.STIMWAVE LLC: NET SALES,
  • TABLE 188.STIMWAVE LLC: KEY STRATERGIES
  • TABLE 189.STRYKER CORP.: COMPANY SNAPSHOT
  • TABLE 190.STRYKER CORP.: OPERATING SEGMENTS
  • TABLE 191.STRYKER CORP.: PRODUCT PORTFOLIO
  • TABLE 192.STRYKER CORP.: NET SALES,
  • TABLE 193.STRYKER CORP.: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1.PARESTHESIA TREATMENT MARKET SEGMENTATION
  • FIGURE 2.PARESTHESIA TREATMENT MARKET,2021-2031
  • FIGURE 3.PARESTHESIA TREATMENT MARKET,2021-2031
  • FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 5.PORTER FIVE-1
  • FIGURE 6.PORTER FIVE-2
  • FIGURE 7.PORTER FIVE-3
  • FIGURE 8.PORTER FIVE-4
  • FIGURE 9.PORTER FIVE-5
  • FIGURE 10.TOP PLAYER POSITIONING
  • FIGURE 11.PARESTHESIA TREATMENT MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 12.PARESTHESIA TREATMENT MARKET,BY DISEASE TYPE,2021(%)
  • FIGURE 13.COMPARATIVE SHARE ANALYSIS OF ACUTE PARESTHESIA PARESTHESIA TREATMENT MARKET,2021-2031(%)
  • FIGURE 14.COMPARATIVE SHARE ANALYSIS OF CHRONIC PARESTHESIA PARESTHESIA TREATMENT MARKET,2021-2031(%)
  • FIGURE 15.PARESTHESIA TREATMENT MARKET,BY TREATMENT,2021(%)
  • FIGURE 16.COMPARATIVE SHARE ANALYSIS OF IMMUNOSUPPRESSANT PARESTHESIA TREATMENT MARKET,2021-2031(%)
  • FIGURE 17.COMPARATIVE SHARE ANALYSIS OF ANTICONVULSANTS PARESTHESIA TREATMENT MARKET,2021-2031(%)
  • FIGURE 18.COMPARATIVE SHARE ANALYSIS OF TOPICAL CREAMS PARESTHESIA TREATMENT MARKET,2021-2031(%)
  • FIGURE 19.COMPARATIVE SHARE ANALYSIS OF ANTIVIRALS PARESTHESIA TREATMENT MARKET,2021-2031(%)
  • FIGURE 20.COMPARATIVE SHARE ANALYSIS OF OTHERS PARESTHESIA TREATMENT MARKET,2021-2031(%)
  • FIGURE 21.PARESTHESIA TREATMENT MARKET,BY DISTRIBUTION CHANNEL,2021(%)
  • FIGURE 22.COMPARATIVE SHARE ANALYSIS OF HOSPITAL PHARMACY PARESTHESIA TREATMENT MARKET,2021-2031(%)
  • FIGURE 23.COMPARATIVE SHARE ANALYSIS OF RETAIL PHARMACY PARESTHESIA TREATMENT MARKET,2021-2031(%)
  • FIGURE 24.COMPARATIVE SHARE ANALYSIS OF ONLINE PHARMACY PARESTHESIA TREATMENT MARKET,2021-2031(%)
  • FIGURE 25.PARESTHESIA TREATMENT MARKET BY REGION,2021
  • FIGURE 26.U.S. PARESTHESIA TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 27.CANADA PARESTHESIA TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 28.MEXICO PARESTHESIA TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 29.FRANCE PARESTHESIA TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 30.GERMANY PARESTHESIA TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 31.UK PARESTHESIA TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 32.ITALY PARESTHESIA TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 33.SPAIN PARESTHESIA TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 34.REST OF EUROPE PARESTHESIA TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 35.JAPAN PARESTHESIA TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 36.CHINA PARESTHESIA TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 37.INDIA PARESTHESIA TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 38.AUSTRALIA PARESTHESIA TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 39.SOUTH KOREA PARESTHESIA TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 40.TAIWAN PARESTHESIA TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 41.REST OF ASIA PACIFIC PARESTHESIA TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 42.BRAZIL PARESTHESIA TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 43.TURKEY PARESTHESIA TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 44.VENEZUELA PARESTHESIA TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 45.SAUDI ARABIA PARESTHESIA TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 46.SOUTH AFRICA PARESTHESIA TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 47.REST OF LAMEA PARESTHESIA TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 48. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 49. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 50. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 51.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 52.COMPETITIVE DASHBOARD
  • FIGURE 53.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 54.ABBOTT LABORATORIES.: NET SALES ,($MILLION)
  • FIGURE 55.ABBVIE INC..: NET SALES ,($MILLION)
  • FIGURE 56.BAXTER INTERNATIONAL INC..: NET SALES ,($MILLION)
  • FIGURE 57.BIO-MEDICAL RESEARCH LTD..: NET SALES ,($MILLION)
  • FIGURE 58.BOSTON SCIENTIFIC CORPORATION.: NET SALES ,($MILLION)
  • FIGURE 59.CIPLA LTD..: NET SALES ,($MILLION)
  • FIGURE 60.CYBERONICS, INC..: NET SALES ,($MILLION)
  • FIGURE 61.ENTEROMEDICS INC..: NET SALES ,($MILLION)
  • FIGURE 62.GLAXOSMITHKLINE PLC..: NET SALES ,($MILLION)
  • FIGURE 63.GLENMARK.: NET SALES ,($MILLION)
  • FIGURE 64.MEDTRONIC.: NET SALES ,($MILLION)
  • FIGURE 65.MERCK.: NET SALES ,($MILLION)
  • FIGURE 66.NEVRO CORP..: NET SALES ,($MILLION)
  • FIGURE 67.OMRON HEALTHCARE, INC..: NET SALES ,($MILLION)
  • FIGURE 68.PFIZER.: NET SALES ,($MILLION)
  • FIGURE 69.STIMWAVE LLC.: NET SALES ,($MILLION)
  • FIGURE 70.STRYKER CORP..: NET SALES ,($MILLION)